Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm

Interventions

DRUG

Fentanyl Citrate Buccal Tablet

Given transmucosally

DRUG

Morphine

Given PO

OTHER

Physical Performance Testing

Complete shuttle walk test

OTHER

Placebo Administration

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT04188418 - Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients | Biotech Hunter | Biotech Hunter